0001104659-20-106117.txt : 20200917
0001104659-20-106117.hdr.sgml : 20200917
20200917162539
ACCESSION NUMBER: 0001104659-20-106117
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200915
FILED AS OF DATE: 20200917
DATE AS OF CHANGE: 20200917
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Love Colin
CENTRAL INDEX KEY: 0001376493
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38596
FILM NUMBER: 201181459
MAIL ADDRESS:
STREET 1: C/O REPLIMUNE GROUP, INC.
STREET 2: 18 COMMERCE WAY
CITY: WOBURN
STATE: MA
ZIP: 10801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Replimune Group, Inc.
CENTRAL INDEX KEY: 0001737953
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 822082553
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: (781) 222-9600
MAIL ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
4
1
a4.xml
4
X0306
4
2020-09-15
0
0001737953
Replimune Group, Inc.
REPL
0001376493
Love Colin
C/O REPLIMUNE GROUP, INC.
500 UNICORN PARK
WOBURN
MA
01801
0
1
0
0
Chief Operating Officer
Common Stock
2020-09-15
4
S
0
3200
23.09
D
1033324
D
Common Stock
2020-09-15
4
S
0
10271
24.11
D
1023053
D
Common Stock
2020-09-15
4
S
0
1529
24.83
D
1021524
D
The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.60 to $23.57.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.68 to $24.67.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.70 to $25.00.
Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,021,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 444,653 shares of the Issuer's common stock, 195,019 of which are exercisable as of the date hereof.
/s/ Jean Franchi, attorney-in-fact
2020-09-17